| abstract |
ABSTRACT OF THE DISCLOSURE Novel 12- and 13-bromoergoline derivatives of the for-mula (I) wherein R is hydrogen or C1-2-alkanoyl, R1 is hydrogen, bromine, or C1-2-alkylthio, wherein at least one of R and R1 is H, and when Br is in the 12-position, R1 is H, and when R1 is bromine C2 C3 is a double bond, R2 is lower alkyl, R3 is NH-CO-NEt2 or NH-CS-NEt2, C9 C10 and C2 C3 each independently is a CC-single or a C=C-double bond, and the hydrogen atom in the 10-position is in the .alpha.-configuration if C9 C10 is a CC-single bond, and the hydrogen atom in the 3-position is in the .alpha.-configuration or .beta.-configuration if C2 C3 is a CC-single bond, or a pharmaceutically acceptable acid addition salt thereof are suitable as medicines for treating psychic disorders of the depressive array of symptoms and also as intermediates. |